TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro Pharmaceutical Industries Ltd. - TARO
and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Taro Pharmaceutical Industries Ltd. (NYSE: TARO) to Sun Pharmaceutical Industries Limited.
- and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Taro Pharmaceutical Industries Ltd. (NYSE: TARO) to Sun Pharmaceutical Industries Limited.
- Under the terms of the proposed transaction, shareholders of Taro will receive $43.00 in cash for each share of Taro that they own.
- KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
- To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .